BioGaia (BIOG) Q4 2024 earnings summary

Executive summary

• Q4 sales reached 365 million SEK, up 23% year-over-year, with strong growth across all regions.

• EBIT for Q4 was 103 million SEK, a 28% increase, with a margin of 28% (up from 27% last year).

• Full-year 2024 sales totaled 1,422.7 million SEK, up 10% year-over-year (11% excluding FX), with all regions positive.

• Adjusted EBIT margin for the year was 34%, excluding the Metabogen impairment loss.

• Board proposed a total dividend of 6.90 SEK per share (698 million SEK), including an extra dividend.

Financial highlights

• Earnings per share for Q4 were 0.81 SEK, up from 0.67 SEK in the prior year.

• Cash flow from operations was 99 million SEK, stable year-over-year; year-end cash was 1,224 million SEK, down 21% year-over-year.

• Gross margin for Q4 was 71%, down from 76% last year, mainly due to inventory write-downs and mix effects.

• Pediatric segment Q4 sales grew 23% to 270 million SEK, adult segment sales grew 20% to 92 million SEK.

• Pediatric business comprised 77% of total annual sales.

Outlook and guidance

• Continued ramp-up of investments in direct markets, especially the U.S., U.K., Canada, Australia, France, and Japan.

• Ongoing digital marketing campaigns expected to drive brand awareness and sales growth.

• Long-term target is an operating margin of at least 34% with increased investments in R&D, product development, and brand building.

• Dividend policy is to pay 50% of profit after tax, with extra dividends of 50–100% if cash flows allow.

• Management expects to mitigate future inventory risks as direct sales expand.